SWOG clinical trial number
SWOG-8851 (INT-0101) (EST-5188)

Comparison of Combination Chemotherapy (CAF) and Chemohormonal Therapy (CAF + Zoladex or CAF + Zoladex + Tamoxifen) In Premenopausal Women With Axillary Node-Positive, Receptor-Positive Breast Cancer

Closed
Phase
Published
Abbreviated Title
CAF vs. CAF+hormonal Tx
Activated
08/01/1989
Closed
02/01/1994

Research committees

Breast Cancer

Treatment

Tamoxifen Goserelin Acetate CAF

Publication Information Expand/Collapse

2005

Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188)

NE Davidson;AM O'Neill;AM Vukov;CK Osborne;S Martino;DR White;MD Abeloff Journal of Clinical Oncology 23(25):5973-5982

2003

Chemohormonal therapy in premenopausal node-positive, receptor-positive breast cancer: an Eastern Cooperative Oncology Group phase III intergroup trial (E5188, INT-0101).

NE Davidson;A O'Neill;A Vukov;CK Osborne;S Martino;D White;M Abeloff Proc of the American Society of Clinical Oncology 22:5(#15)

1999

Effect of chemohormonal therapy in premenopausal, node (+), receptor (+) breast cancer: An Eastern Cooperative Oncology Group phase III intergroup trial (E5188, INT-0101).

N Davison;A O'Neill;T Habermann;CK Osborne;S Martino;D White;MD Abeloff Proc of the American Society of Clinical Oncology 18:67a(#249)

Other Clinical Trials

SWOG Clinical Trial Number
S2206

A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer
Research Committee(s)
Breast Cancer
Symptom Control and Quality of Life
Activated
10/30/2023
Accrual
6%
Open
Phase
SWOG Clinical Trial Number
S2212

TIL Adapted Neo adjuvant Chemotherapy Optimization in Triple negative breast cancer (SCARLET)
Research Committee(s)
Breast Cancer
Activated
07/21/2023
Accrual
13%
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-BR007

A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer
Research Committee(s)
Breast Cancer
Activated
06/07/2021
Open
Phase